Alcidion Group Limited · ASX:ALC
Alcidion — FY2022 Earnings Presentation
30 slides from Alcidion's earnings presentation, Sep 12, 2022
Slide 1: FY22 Results Investor Presentation (ASX announcement cover note)
12 September 2022 Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000 For personal use only FY22 Results Investor Presentation Melbourne, Australia – Alcidion Group Limited (ASX: ALC) Managing Director, Kate Quirke, and Chief Financial Officer, Matt Gepp will hold a series of investor p
Slide 2: Investor presentation FY22 Results September 2022
For personal use only Investor presentation FY22 Results September 2022 COMMERCIAL IN CONFIDENCE 1
Slide 3: Alcidion – a snapshot
Alcidion – a snapshot For personal use only Alcidion Operates in 3 Geographies • Alcidion‘s purpose is to transform healthcare with (% FY22 Revenue) smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide ANZ UK • Focus on
Slide 4: Alcidion platform: 'Built for clinicians'
Alcidion platform: ‘Built for clinicians’ For personal use only Leveraging the Miya Precision platform along with Silverlink PCS PAS, Alcidion can deliver a cloud-native modern, modular, open architecture, EPR platform taking on the major global incumbents Partner Products Alcidion Platform Modern,
Slide 5: Market outlook
Market outlook For personal use only Hospitals are increasingly seeking seamless, digital solutions to manage clinical workflow Transition to digital Increasing industry Increasing demand Increasing market support & funding for seamless clinical interest & activity solutions Shift towards digital wi
Slide 6: Alcidion positioning
Alcidion positioning For personal use only Cloud native, modern modular platform Long-term contracts with embedded Market tailwinds and increased improving hospital efficiencies and technology driving recurring spending driving potential clinical decision-making revenues opportunistic M&A / consolid
Slide 7: Value proposition to customers
Value proposition to customers For personal use only Incumbents Cloud native • Primarily on premise or data centre deployments ✓ Full cloud-first EPR solution • Progressively developing cloud ability albeit unproven and ✓ Reduces capital costs and increases efficiency limited to certain functionalit
Slide 8: Growing momentum
Growing momentum 7 December, 2021 Acquisition of Silverlink PCS For personal use only 2 March 2021 Software Limited completed with $55.0M capital raising 4 April, 2022 Medications Management to fund acquisition contract with NZ DHBs 9TCV First two renewals for $0.6M over 6 mths) Silverlink PCS solut
Slide 9: FY22 Summary
For personal use only FY22 Summary Commercial in Confidence
Slide 10: FY22 – Financial Highlights
FY22 – Financial Highlights1 For personal use only Strong performance in key financial metrics and record sold revenue heading into FY23 Revenue $34.4M 33% Recurring Revenue $23.3M 42% Gross Margin 85.8% 2.5pts Sold Revenue for FY23 $28.3M 87% Underlying EBITDA2 $0.9M $0.4M FY22 TCV3 new sales $57.7
Slide 11: FY22 - Revenue
FY22 - Revenue For personal use only Half-on- half Revenue revenue by region Recurring / non- % recurring Revenue revenue by region 10
Slide 12: Profit & Loss
Profit & Loss For personal use only Profit & loss ($000) FY22 FY21 % change Key Comments Recurring revenue 23,274 16,343 42% • Record FY22 revenue of $34.4m, up 33% on FY21 Non-recurring revenue 11,081 9,539 16% Total revenue 34,355 25,882 33% A$M Products Product Imp Services Total Direct costs (4,
Slide 13: Balance Sheet
Balance Sheet For personal use only Balance sheet ($000) FY22 FY21 Key Comments Cash & cash equivalents 17,339 25,027 • Strong balance sheet with $17.3M cash and no debt Trade & other receivables 7,251 4,114 Other assets 1,672 1,206 • Unearned revenue of $12.9M (up $5.8M) reflects revenue invoiced i
Slide 14: Cash Flow
Cash Flow For personal use only Cash flow ($000) FY22 FY21 Key Comments Receipts from customers 41,449 32,046 Payments to suppliers & employees (40,275) (30,510) Interest recevied 24 12 • Record $41.4M receipts from customers, a $9.4M (29%) increase on FY21 Finance costs (68) (3) Income tax paid (13
Slide 15: FY22 Corporate Summary
FY22 Corporate Summary For personal use only Executed key operational and corporate strategies which underpin future growth profile • In December 2021, acquired Silverlink PCS, one of last few remaining PAS1 providers servicing UK NHS Silverlink • 12 long-standing NHS Trusts (11 new for Alcidion) wi
Slide 16: FY22 – New & Renewed Contracts
FY22 – New & Renewed Contracts For personal use only • Queen’s Hospital Burton: South Tees NHS Hospitals: New three-year contract for ExtraMed’s IPFM, first new contract win following ExtraMed acquisition • Royal Derby Hospital: Three-year contract extension, ExtraMed’s IPFM licence & support • NHS
Slide 17: Market positioning and opportunity
For personal use only Market positioning and opportunity Commercial in Confidence
Slide 18: Overview – UK market dynamics
Overview – UK market dynamics For personal use only *For illustrative purposes only Government Bodies NHS England Alcidion’s Customer (Future, ICS* ICS #1 ICS #2 (42) albeit still emerging) Trusts Alcidion’s Customer (Today) T #1 T #2 T #3 T #4 T #5 T #6 (~146 Acute) Hospitals H1 H2 H3 H4 H5 H6 H7 H
Slide 19: Increasing importance of ICS in UK Market
Increasing importance of ICS in UK Market For personal use only What are Integrated Care Systems (ICS)? 42 • Partnerships that bring together NHS health services across a geographical area (i.e. aggregation of Trusts (who may have multiple hospitals) in a region) ICSs across England • Aim to integra
Slide 20: UK NHS – Frontline digitisation strategy
UK NHS – Frontline digitisation strategy For personal use only • Targeting 90% of Trusts to have an EPR procured by December 2023 Coverage • Targeting 100% of Trusts to have EPR live by March 2025 • As many trusts as possible will meet minimum capability standard for digitation Capability (equivalen
Slide 21: Frontline digitisation program
Frontline digitisation program For personal use only Targeting for all Trusts to meet the minimum digital foundation (procured) by December 2023 Trusts have been assessed on their current digital maturity and have been placed into groups depending on that assessment – Group 0 Low digital maturity an
Slide 22: Solving with a modern, modular EPR offering
Solving with a modern, modular EPR offering For personal use only A modular EPR built for clinicians Patient Scheduling Flow Decision Medications Support PAS Messaging Existing Miya Functionality Acquisition of Silverlink Partner with specialist systems Leveraging the Miya Precision platform along w
Slide 23: Modular sales approach driving uplift in TCV
Modular sales approach driving uplift in TCV For personal use only Modular Miya Precision supports ‘land and expand’ strategy to full EPR *For illustrative purposes only Ability over time to replicate full EPR contract value ($20-$40m) via modular add-ons $30.0m $30m Several customers validating $25
Slide 24: UK Market Penetration
UK Market Penetration For personal use only Material revenue opportunity driven by modular product upsell, along with new customer wins Alcidion NHS penetration in UK Market Contract Size Upside Potential Total Acute 39 (~27%) 145 Approx. • Current EPR offerings based on legacy tech with modern Trus
Slide 25: Silverlink transition
Silverlink transition For personal use only • Acquired Silverlink in December 2021 • All HR and operational functions completed and migrated to Alcidion • Client engagement ongoing • Phase 1 development – PCS to the cloud “proof • Integration • PCS to Cloud • Client of HR and engagement of concept”
Slide 26: Australia - Market Penetration
Australia - Market Penetration For personal use only Strong relationships incorporating trusted services & product offering provide foundation for expansion Alcidion penetration in AUS Market Growth Focus 75 1• Validation of scalability of Miya Precision as Longitudinal Health services 33 (~44%) Hea
Slide 27: Current NZ Market Penetration
Current NZ Market Penetration For personal use only Continuing to hold strong market position whilst progressing strategic discussions Alcidion penetration in NZ Market Key NZ Contracts & Growth Focus 1• NZ Health Reform: Central entity established as well as Maori Health Authority DHBs 14 (~70%) 20
Slide 28: Starting FY23 with a strong contracted revenue base
Starting FY23 with a strong contracted revenue base For personal use only Key Comments • $28.3M of contracted revenue to be recognised in FY23, 87% higher than at same time last year • Further $2.9M of scheduled renewal, expected to be converted to contracted revenue over FY23 Key Growth Drivers: Ne
Slide 29: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidio
Slide 30: For personal use only
For personal use only